XML 13 R4.htm IDEA: XBRL DOCUMENT v3.4.0.3
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2016
Mar. 31, 2015
Income Statement [Abstract]    
Net sales $ 1,641,028 $ 288,277
Cost of sales 1,337,942 74,216
Gross Profit 303,086 214,061
Compensation and related expenses (240,455) (85,390)
Professional fees (69,315) (35,508)
General and administrative expenses (98,412) (85,329)
Operating (Loss) Income (105,096) 7,834
Interest (expense) (3,063) (10,468)
Net (Loss) Before Taxes $ (108,159) (2,634)
Deferred income tax benefit 4,300
Net (Loss) Income $ (108,159) $ 1,666
Net (Loss) income attributable to noncontrolling interests (46,110)
Net (Loss) income attributable to Immudyne, Inc. $ (62,049) $ 1,666
Basic and diluted (loss) income per share attributable to Immudyne, Inc. $ 0.00 $ 0.00
Average number of common shares outstanding    
Basic 32,010,375 30,729,973
Diluted $ 32,010,375 $ 31,363,306